Clinical Trial Update: Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating AGS-003, an autologous dendritic cell–based immunotherapy, for biologic activity and safety in patients with newly diagnosed stage …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AGS-003 (RNA-loaded autologous dendritic cell vaccine)

Snippet

Sponsor: Argos Therapeutics | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED